Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?-Reference-Cited by-同舟云学术

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

Published:2019-12 Issue: Volume:121 Page:108705
ISSN:0720-048X
Container-title:European Journal of Radiology
language:en
Short-container-title:European Journal of Radiology

Author:

van der Velden Bas H.M.,Bismeijer Tycho,Canisius Sander,Loo Claudette E.,Lips Esther H.,Wesseling Jelle,Viergever Max A.,Wessels Lodewyk F.A.,Gilhuijs Kenneth G.A.

Funder

Dutch Technology Foundation STW

Netherlands Organisation for Scientific Research

Ministry of Economic Affairs

Dutch Cancer Society

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference34 articles.

1. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J. Natl. Cancer Inst.,2014

2. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers;Selli;Breast Cancer Res.,2016